Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gelteq Limited ( (GELS) ) just unveiled an update.
On December 9, 2025, Gelteq Limited announced that it will be providing a virtual presentation hosted by Investor Summit to select private investors. This presentation highlights Gelteq’s innovative drug delivery platform, which addresses significant challenges in the pharmaceutical and supplement industries, such as poor adherence, pill fatigue, and the oral delivery of insoluble ingredients. The company’s patented gel technology has demonstrated improved bioavailability and faster absorption for both water-soluble and oil-soluble compounds, potentially expanding its commercial scope and industry impact.
More about Gelteq Limited
Gelteq Limited is a global clinical and science-based company, founded in 2017 in Melbourne, Australia. It specializes in the formulation, development, and manufacturing of ingestible gel products for drug delivery. The company aims to improve patient compliance with an easy-to-swallow and enjoyable delivery format for medications and nutritional supplements. Gelteq holds multiple patent families covering various applications for its proprietary gel technology and has recently delivered pilot nutraceutical orders in China, the USA, and Australia.
Average Trading Volume: 1,076,237
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.68M
See more insights into GELS stock on TipRanks’ Stock Analysis page.